Press Release
More than 100 diplomatic envoys to China from 50 countries land at starting point of Silk Road and to embark on economic, trade and cultural tour of Xi’an
On May 10th, more than 100 diplomatic envoys to China from 50 countries have arrived in Xi’an, to attend the five-day event of “Bring the starting point of the Silk Road to the world”, 2021 Economic Trade and Cultural Tour of Xi’an for Diplomatic Envoys to China.
The staff of the event organizing committee went to Xi’an Xianyang International Airport to guarantee the reception work to go smoothly. Nearly one hundred etiquette girls and volunteers greeted the foreign envoys at the arrivals exit of the terminal building. By 17:00, all the diplomatic envoys have arrived in Xi’an and checked into the Grand Wyndham Hotel Xi’an.
In the afternoon, the diplomatic envoys went to “Wengcheng” (the defensive enclosure) of Xi’an Yongning Gate to participate in the ancient-style entering ceremony. This is the noblest way that the Shaanxi Provincial People’s Government greet guests from afar. All the diplomatic envoys’ presence in “Wengcheng” made an instant hit in Xi’an. The local citizens took photos, videos and sent posts on their WeChat moments, which caused a great sensation.
A lively scene was presented that night in the “Wengcheng” of Yongning Gate. For most diplomatic envoys who are rich in experiences and knowledge, it is the first time to participate in such a high standard and large scale ancient-style entering ceremony. Their excitement was beyond words. They just raised their thumbs from time to time and praised “OK, OK!”. An envoy from Nepal who had lived in China for nine years said in fluent Chinese, “The ancient city-entering ceremony is so amazing. The night scenery of Xi’an is so beautiful that I will never forget it.”
The 5th Silk Road International Expo and Investment and Trade Fair for Cooperation between East and West will solemnly open at Xi ‘an International Convention and Exhibition Center on May 11. As the branch session of the 5th Silk Road Expo, the event of “Bring the Starting Point of the Silk Road to the World” 2021 Economic Trade and Cultural Tour of Xi’an for Diplomatic Envoys to China will surely add much glamour to the Expo.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
United Kingdom, 12th Dec 2025 – Recently, the cryptocurrency market has faced renewed volatility. With major liquidity engines collapsing and up to $5 billion flowing out of ETFs, Bitcoin (BTC) prices are under pressure, and market uncertainty is on the rise.
ETF funds are generally seen as an important indicator of institutional investor confidence. Their outflow often signals tightening market liquidity and higher price volatility.
Analyst Ted Piro pointed out that, given the current market environment, investors should approach such fund outflows with caution. He asked:
Will BTC experience another major drop?
If institutions reduce their holdings, the increase in Bitcoin supply could put downward pressure on prices. Historical data shows that large-scale fund movements often precede price adjustments, further increasing market uncertainty.
As a result, retail investors have begun to adjust their strategies. Instead of relying solely on short-term market opportunities, they are focusing on early accumulation, wealth building, and creating sustainable cash flow. In discussions about BTC investment strategies, Investor Hash’s automated digital asset platform is frequently mentioned, allowing users to participate in managed investment plans and earn daily returns without technical setup or manual trading.
Why is Investor Hash So Popular?
Investor Hash is known for its:
- Green energy-powered data centers, ensuring sustainable operation.
- Transparent and automated asset management, enabling predictable returns.
- Regulated infrastructure: No hardware, maintenance, or technical expertise is required; users simply allocate funds into digital asset plans to earn stable returns.
The platform is registered in the UK and regulated by authorities. It uses international-grade security systems, including McAfee® and Cloudflare®, to protect user funds and data to a bank-level standard. All earnings are processed via smart contracts in real-time, ensuring transparency and traceability. Investor Hash currently serves users in over 180 countries and regions and is trusted by over 2 million investors worldwide.
How Does Investor Hash Ensure Fund Security?
Investor Hash prioritizes fund safety with a multi-layered, comprehensive protection system:
- Cold Wallet Custody: Over 80% of client funds are stored offline, minimizing risk.
- Asset Insurance: All digital assets are covered by international insurance, providing global protection.
- AI Smart Risk Control: AI monitors transactions in real-time to prevent fraud, money laundering, and abnormal fund movements.
- External Audits and Monitoring: PwC conducts regular security and compliance audits to ensure transparency.
- Global Security Network: Enterprise-grade Cloudflare firewall and McAfee cloud security provide round-the-clock protection.
This systematic security architecture allows Investor Hash to offer a compliant, auditable, and uninterrupted investment environment.
How to Participate in Investor Hash and Earn Daily Returns
Investors can participate in three simple steps:
- Register an Account – Sign up with your email and receive a $15 registration bonus.
- Select an Investment Plan – Invest as little as $100 to start participating in automated digital asset plans.
- Start Asset Management – After allocating funds, returns are credited daily, and principal is automatically returned when the plan expires.
Investment Plan Examples (for illustration only, not guaranteed returns):
| Plan Type | Investment Amount | Term | Total at Maturity (Principal + Estimated Returns) |
|---|---|---|---|
| Starter Plan | $100 | 2 days | $106 |
| Basic Plan | $1,000 | 12 days | $1,156 |
| Classic Plan | $5,000 | 25 days | $6,875 |
| Advanced Plan | $12,000 | 35 days | $19,140 |
| Advanced Plan (Large) | $30,000 | 40 days | $51,600 |
| Super Plan | $120,000 | 49 days | $261,120 |
Click here to learn more about Investor Hash investment plans
Conclusion
While the $5 billion ETF outflow and liquidity engine collapse have put short-term pressure on Bitcoin prices, whether BTC will experience another major drop depends on multiple factors: institutional behavior, macroeconomic trends, and market sentiment.
For retail investors, understanding market risk and adopting a prudent strategy is critical. Leveraging regulated platforms like Investor Hash to participate in automated digital asset plans can help achieve stable, predictable returns in a volatile market.
Visit Investor Hash today to explore investment plans and earn daily returns.
Media Contact
Organization: Investor Hash
Contact Person: Lola Farmer
Website: https://investorhash.com/
Email: Send Email
Country:United Kingdom
Release id:38886
Disclaimer: The information provided above is for general informational purposes only and does not constitute financial, investment, or trading advice. Cryptocurrency markets are highly volatile, and readers should conduct their own independent research and consult with a qualified professional before making any financial decisions.
The post Crypto Liquidity Engine Collapses: Will BTC Drop Again After $5 Billion ETF Outflow appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
CMS (867/8A8): NDA of Innovative Drug Y-3 for Injection for Acute Ischemic Stroke Accepted in China
SHENZHEN, CHINA – China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that on 11 December 2025, the New Drug Application (NDA) of Class 1 Innovative Drug Y-3 for Injection (proposed English generic name: Loberamisal for Injection) (“Y-3 for Injection” or the “Product”) has been accepted by National Medical Products Administration of the People’s Republic of China (NMPA). The Product is a brain cytoprotectant indicated for the treatment of acute ischemic stroke.
With well-defined targets and clear mechanism of action, Y-3 for Injection is able to exert multiple therapeutic effects. As the world’s first brain cytoprotectant developed based on the important targets PSD95-nNOS and MPO, in the pathological processes of stroke, Y-3 for Injection acts on multiple key pathological processes of the ischemic cascade in ischemic stroke. Through multi-target, highly selective synergy, it is more conducive to exerting brain cytoprotective effects. The Product has an excellent therapeutic effect on ischemic stroke and the potential to prevent post-stroke depression and anxiety symptoms.
Y-3 for Injection demonstrates excellent clinical data with excellent efficacy and a favorable safety profile. The results of Phase II clinical trial of the Product in China indicated that among patients with ischemic stroke within 48 hours of onset, patients in the Y-3 group (40mg, qd) demonstrated a significantly higher proportion of patients achieving an excellent functional outcome (mRS of 0-1) at 90 days than those in the placebo group, with a rate difference of 16%. The Phase III clinical trial of the Product in China was conducted by Beijing Tiantan Hospital, Capital Medical University as the leading site. It has enrolled nearly 1,000 patients with acute ischemic stroke within 48 hours of onset across approximately 40 research centers nationwide, aiming to evaluate the efficacy and safety of Y-3 for Injection in treating patients with acute ischemic stroke within 48 hours of onset. The Phase III clinical study met the primary efficacy endpoint, with patients achieving significant clinical benefits and an overall favorable safety profile. The key study results are planned to be presented at international academic conferences, and the full study will be published in international academic journals.
The Central Nervous System (CNS) is one of the core advantageous fields of CMS, where a deeply integrated layout has been progressively established. The product portfolio has solidified the market foundation, including the marketed innovative drug VALTOCO (Diazepam Nasal Spray), the original brand drug Deanxit (Flupentixol and Melitracen Tablets), and the improved new drug ZUNVEYL (Benzgalantamine Gluconate Enteric-coated Tablets), which is currently under NDA review. The addition of Y-3 for Injection will further strengthen the product portfolio, generating highly efficient synergies in terms of expert networks and market resources. It is expected that if approved for marketing, Y-3 for Injection will bring a new generation of brain cytoprotectant with excellent efficacy and more comprehensive therapeutic effects to Chinese patients with ischemic stroke. Leveraging the successful commercialization experience and compliant and efficient operation system, the Group will accelerate the accessibility of innovative therapies to benefit more patients.
More Information about Y-3 for Injection
The pathological processes of acute ischemic stroke are highly complex and interconnected. There is an urgent clinical need for multi-target, multi-mechanism coordinated interventions to achieve more effective regulation of the complex ischemic cascade, thereby improving treatment outcomes and enhancing patients’ quality of life. Y-3 for Injection is able to uncouple PSD95-nNOS, inhibit MPO activity, and enhance the activity of α2-GABAA receptor (a subtype of GABAA receptor with antidepressant and anxiolytic effects). With this multi-target, highly selective synergistic mechanism, it is expected to achieve a technological breakthrough in the simultaneous intervention of “stroke treatment and prevention of post-stroke depression and anxiety”, making Y-3 for Injection a promising novel brain cytoprotectant with excellent efficacy and more comprehensive therapeutic effects.
The results of Phase II clinical trial of Y-3 for Injection for the treatment of acute ischemic stroke were presented as an oral poster at the 10th European Stroke Organisation Conference in 2024 (ESOC 2024). It indicated that among patients with ischemic stroke within 48 hours of onset, patients in the Y-3 group (20mg, 40mg, 60mg, qd) demonstrated a significantly higher proportion of patients achieving an excellent functional outcome (mRS of 0-1) at 90 days than those in the placebo group (20mg: 67.8% vs 60.7%, 40mg: 76.7% vs 60.7%, 60mg: 70.0% vs 60.7%). Moreover, the Product showed comparable safety to placebo in acute ischemic stroke patients, exhibiting good tolerability.
On 24 August 2023, the Group through its wholly-owned subsidiary entered into a Collaboration Agreement (the “Agreement”) with Neurodawn Pharmaceutical Co., Ltd. (“NeuroDawn”), a clinical needs-oriented pharmaceutical company driven by innovation and R&D. In accordance with the Agreement, the Group obtains an exclusive promotion right in mainland China, the Hong Kong Special Administrative Region, and the Macau Special Administrative Region. The term of the Agreement is permanent.
About Stroke
According to the Guideline for Prevention and Treatment of Cerebrovascular Disease (2024 Edition) issued by the National Health Commission, approximately 3.94 million new stroke cases occur in China each year, accounting for one-third of the global new cases[1]. Among these, ischemic stroke accounts for about 72%, with over 2.8 million new cases annually; the number of existing stroke patients in China has exceeded 28 million[1]. Data from China’s cause-of-death monitoring in 2021 shows that stroke-related deaths accounted for 23% of the national total deaths[1]. Over the past three decades, the disease burden of stroke-related disabilities in China has continued to increase[1]. Coupled with factors such as the accelerating aging of the population, the pressure of stroke prevention and control will further intensify in the future, posing enormous challenges to patients’ families and society[1]. In addition, post-stroke depression and anxiety are common complications of stroke, with incidence rates of approximately 30% and 25% respectively[2]. They can hinder the recovery of patients’ neurological functions, even increase the risk of death, and severely affect patients’ prognosis. Y-3 for Injection holds significant potential value for the long-term neurological function improvement and overall prognosis of a vast number of stroke patients, indicating broad market prospects.
About CMS
CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.
CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.
CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.
Reference
- National Health Commission of the People’s Republic of China. Guideline for Prevention and Treatment of Cerebrovascular Disease (2024 Edition) [J]. Chinese Journal of Magnetic Resonance Imaging, 2025, 16(1): 1-8. DOI: 10.12015/issn.1674-8034.2025.01.001.
- Chen Xinyu, Lyu Xiaohan, Li Ruina, et al. Post-Stroke Anxiety [J]. International Journal of Cerebrovascular Disease, 2022, 30(2): 129-133. DOI: 10.3760/cma.j.issn.1673-4165.2022.02.010.
CMS Disclaimer and Forward-Looking Statements
This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.
This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.
Media Contact
Brand: China Medical System Holdings Ltd.
Contact: CMS Investor Relations
Email: ir@cms.net.cn
Website: https://web.cms.net.cn/en/home/
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Worcester, Massachusetts, 11 Dec 2025, ZEX PR WIRE, As debates over privacy, free speech, and policing continue to unfold nationwide, local residents like Kevin Wall of Worcester are encouraging more community awareness around civil liberties and individual rights.
Wall, who has lived in Worcester for over a decade, says many people care about these issues but don’t always know where to start. “Most people I talk to want things to be fair and transparent,” Kevin Wall said. “They’re concerned about surveillance, about how schools handle discipline, about what kind of data companies and the government collect. But they don’t always feel equipped to speak up.”
Though not affiliated with any organization, Wall often shares resources from civil rights groups like the ACLU, especially those related to Massachusetts policies and digital rights. He follows court decisions and legislative changes and encourages others to do the same. “You don’t have to be an expert. Just being informed helps you spot when something isn’t right.”
In Massachusetts, recent civil liberties conversations have included facial recognition technology bans, school-based surveillance tools, bail reform, and expanded voting access. Organizations like the ACLU of Massachusetts have weighed in on many of these issues, publishing legal analysis and policy recommendations.
Worcester itself has seen growing interest in these topics. In recent years, the city has hosted forums on data privacy, transparency in school policies, and police oversight. Wall sees this as a sign of a more engaged public. “It’s not about being political,” he said. “It’s about understanding how systems work and making sure people are treated fairly.”
He says the rise of AI and digital tracking tools has made the public role more important than ever. “The tools are changing fast. You need people who are paying attention and asking questions.”
Wall is particularly focused on issues that affect everyday life: student discipline policies, use of technology in public spaces, and due process protections in local courts. “You can’t protect your rights if you don’t know what they are,” he said. “Groups like the ACLU do a good job breaking it down.”
For Worcester residents looking to get more involved, Wall recommends starting small. “Read a case summary. Sign up for an email list. Go to a local meeting. Even asking questions at a school board or city council meeting makes a difference.”
While he doesn’t speak publicly or run a group, Wall believes that quiet civic engagement still matters. “There are lots of ways to contribute without being front and center.”
He hopes more residents in Worcester will take interest in how rights are shaped and protected at the local level. “We all benefit when more people pay attention. Whether it’s about speech, privacy, education, or equal treatment, these issues affect all of us.”
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Crypto Liquidity Engine Collapses: Will BTC Drop Again After $5 Billion ETF Outflow
CMS (867/8A8): NDA of Innovative Drug Y-3 for Injection for Acute Ischemic Stroke Accepted in China
Kevin Wall Worcester: Local Voices Add Perspective as Civil Liberties Take Center Stage
Benzinga Money Article Discusses How to Become Part of the 12% of Retirees Who Have Achieved the Recommended $550,000 Minimum Retirement Savings Threshold
Apu Apustaja Conquers New York with Lively Street Ads, Including Times Square Billboard
Bay Smokes Maintains Quality Amid Legislative Changes in the Hemp Industry
-
Press Release6 days ago
Author of Journey to Forever Meets with Film Producer to Discuss Screen Potential
-
Press Release6 days ago
The Attic Insulation Specialists Inc. Expands Full-Service Home Energy and Safety Solutions Across Southern California
-
Press Release7 days ago
Operational Police Protective Services Introduces Elite Security Solutions for High-Profile Corporate and Entertainment Events
-
Press Release6 days ago
Jack Botanicals Sets New Industry Standard with Premium Quality Kratom and Best Kratom Vendor
-
Press Release7 days ago
Bougainville Launches Offshore Gaming and Financial Authorities
-
Press Release7 days ago
Mary Drucker Palm Beach Dental Assistant Champions Oral Health Through Local Outreach
-
Press Release6 days ago
NUICC Launches South India Regional Chamber in Bengaluru to Propel U.S.–India Trade and Innovation
-
Press Release6 days ago
Safari Soles Tours Reaches 2,000th 5-Star Review on Tripadvisor and Becomes Best Rated Safari Operator in Tanzania